BCMA CAR T-cell therapy arrives for multiple myeloma: a reality

被引：8
|
作者：
Cho, Shih-Feng [1 ,2 ,3 ,4 ]
Anderson, Kenneth C. [1 ,2 ]
Tai, Yu-Tzu [1 ,2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA
[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ, Coll Med, Fac Med, Kaohsiung, Taiwan
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2018年 / 6卷
基金：
美国国家卫生研究院;
关键词：
MATURATION ANTIGEN; REMISSIONS; RECEPTORS;
D O I：
10.21037/atm.2018.11.14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient's Monitoring after CAR T-Cell Therapy
    Puglianini, Omar Alexis Castaneda
    Peres, Lauren C.
    Hansen, Doris K.
    Nishihori, Taiga
    Grajales-Cruz, Ariel F.
    Blue, Brandon J.
    Brayer, Jason
    Freeman, Ciara L.
    Shain, Kenneth H.
    Liu, Hien D.
    Ochoa, Jose
    Locke, Frederick L.
    Baz, Rachid C.
    Alsina, Melissa
    BLOOD, 2022, 140 : 7538 - 7539
  • [32] Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma
    Reyes, Kevin R.
    Huang, Chiung-Yu
    Lo, Mimi
    Arora, Shagun
    Chung, Alfred
    Wong, Sandy W.
    Wolf, Jeffrey
    Olin, Rebecca L.
    Martin, Thomas
    Shah, Nina
    Banerjee, Rahul
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (06): : 350 - 355
  • [33] Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
    Samur, Mehmet Kemal
    Fulciniti, Mariateresa
    Samur, Anil Aktas
    Bazarbachi, Abdul Hamid
    Tai, Yu-Tzu
    Prabhala, Rao
    Alonso, Alejandro
    Sperling, Adam S.
    Campbell, Timothy
    Petrocca, Fabio
    Hege, Kristen
    Kaiser, Shari
    Loiseau, Herve Avet
    Anderson, Kenneth C.
    Munshi, Nikhil C.
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [34] Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
    Mehmet Kemal Samur
    Mariateresa Fulciniti
    Anil Aktas Samur
    Abdul Hamid Bazarbachi
    Yu-Tzu Tai
    Rao Prabhala
    Alejandro Alonso
    Adam S. Sperling
    Timothy Campbell
    Fabio Petrocca
    Kristen Hege
    Shari Kaiser
    Hervé Avet Loiseau
    Kenneth C. Anderson
    Nikhil C. Munshi
    Nature Communications, 12
  • [35] BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma
    Yang, Jinrong
    Zhou, Weilin
    Li, Dan
    Niu, Ting
    Wang, Wei
    CANCER LETTERS, 2023, 553
  • [36] CAR T-cell therapy in multiple myeloma: more room for improvement
    Teoh, Phaik Ju
    Chng, Wee Joo
    BLOOD CANCER JOURNAL, 2021, 11 (04)
  • [37] CAR T-cell therapy for multiple myeloma: state of the art and prospects
    van de Donk, Niels W. C. J.
    Usmani, Saad Z.
    Yong, Kwee
    LANCET HAEMATOLOGY, 2021, 8 (06): : E446 - E461
  • [38] CAR T-cell therapy in multiple myeloma: more room for improvement
    Phaik Ju Teoh
    Wee Joo Chng
    Blood Cancer Journal, 11
  • [39] Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective
    Shih, Steven Chun-Min
    Bhella, Sita
    CURRENT ONCOLOGY, 2024, 31 (07) : 3949 - 3967
  • [40] Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma
    Choi, Taewoong
    Kang, Yubin
    PHARMACOLOGY & THERAPEUTICS, 2022, 232
12345